Literature DB >> 24394480

Defining risk groups to yellow fever vaccine-associated viscerotropic disease in the absence of denominator data.

Stephen J Seligman1, Joel E Cohen, Yuval Itan, Jean-Laurent Casanova, John C Pezzullo.   

Abstract

Several risk groups are known for the rare but serious, frequently fatal, viscerotropic reactions following live yellow fever virus vaccine (YEL-AVD). Establishing additional risk groups is hampered by ignorance of the numbers of vaccinees in factor-specific risk groups thus preventing their use as denominators in odds ratios (ORs). Here, we use an equation to calculate ORs using the prevalence of the factor-specific risk group in the population who remain well. The 95% confidence limits and P values can also be calculated. Moreover, if the estimate of the prevalence is imprecise, discrimination analysis can indicate the prevalence at which the confidence interval results in an OR of ∼1 revealing if the prevalence might be higher without yielding a non-significant result. These methods confirm some potential risk groups for YEL-AVD and cast doubt on another. They should prove useful in situations in which factor-specific risk group denominator data are not available.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24394480      PMCID: PMC3919230          DOI: 10.4269/ajtmh.13-0542

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  13 in total

1.  History of thymoma and yellow fever vaccination.

Authors:  Rachel Barwick Eidex
Journal:  Lancet       Date:  2004 Sep 11-17       Impact factor: 79.321

2.  A case of yellow fever vaccine-associated disease.

Authors:  Heather Isenman; Andrew Burns
Journal:  N Z Med J       Date:  2012-02-10

3.  Adverse event reports following yellow fever vaccination.

Authors:  Nicole P Lindsey; Betsy A Schroeder; Elaine R Miller; M Miles Braun; Alison F Hinckley; Nina Marano; Barbara A Slade; Elizabeth D Barnett; Gary W Brunette; Katherine Horan; J Erin Staples; Phyllis E Kozarsky; Edward B Hayes
Journal:  Vaccine       Date:  2008-09-20       Impact factor: 3.641

4.  Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events.

Authors:  Alena Y Khromava; Rachel Barwick Eidex; Leisa H Weld; Katrin S Kohl; Robert D Bradshaw; Robert T Chen; Martin S Cetron
Journal:  Vaccine       Date:  2005-05-09       Impact factor: 3.641

5.  Immunological conditions of children with BCG disseminated infection.

Authors:  J L Casanova; E Jouanguy; S Lamhamedi; S Blanche; A Fischer
Journal:  Lancet       Date:  1995-08-26       Impact factor: 79.321

Review 6.  Review of the risks and benefits of yellow fever vaccination including some new analyses.

Authors:  Thomas P Monath
Journal:  Expert Rev Vaccines       Date:  2012-04       Impact factor: 5.217

7.  Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes.

Authors:  Bali Pulendran; Joseph Miller; Troy D Querec; Rama Akondy; Nelson Moseley; Oscar Laur; John Glidewell; Nathan Monson; Tuofu Zhu; Haiying Zhu; Sylvija Staprans; David Lee; Margo A Brinton; Andrey A Perelygin; Claudia Vellozzi; Philip Brachman; Susan Lalor; Dirk Teuwen; Rachel B Eidex; Marty Cetron; Frances Priddy; Carlos del Rio; John Altman; Rafi Ahmed
Journal:  J Infect Dis       Date:  2008-08-15       Impact factor: 5.226

8.  Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.

Authors:  J G Breugelmans; R F Lewis; E Agbenu; O Veit; D Jackson; C Domingo; M Böthe; W Perea; M Niedrig; B D Gessner; S Yactayo
Journal:  Vaccine       Date:  2013-02-07       Impact factor: 3.641

9.  Yellow fever virus vaccine-associated deaths in young women.

Authors:  Stephen J Seligman
Journal:  Emerg Infect Dis       Date:  2011-10       Impact factor: 6.883

Review 10.  Revisiting Crohn's disease as a primary immunodeficiency of macrophages.

Authors:  Jean-Laurent Casanova; Laurent Abel
Journal:  J Exp Med       Date:  2009-08-17       Impact factor: 14.307

View more
  5 in total

Review 1.  Life-Threatening Infections Due to Live-Attenuated Vaccines: Early Manifestations of Inborn Errors of Immunity.

Authors:  Laura Pöyhönen; Jacinta Bustamante; Jean-Laurent Casanova; Emmanuelle Jouanguy; Qian Zhang
Journal:  J Clin Immunol       Date:  2019-05-23       Impact factor: 8.317

Review 2.  Yellow fever in Africa and the Americas: a historical and epidemiological perspective.

Authors:  Jean-Philippe Chippaux; Alain Chippaux
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2018-08-25

3.  Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines.

Authors:  Nicholas Hernandez; Giorgia Bucciol; Leen Moens; Jérémie Le Pen; Mohammad Shahrooei; Ekaterini Goudouris; Afshin Shirkani; Majid Changi-Ashtiani; Hassan Rokni-Zadeh; Stephen J Seligman; Laurent Abel; Paul Hertzog; Nico Marr; Reinaldo de Menezes Martins; Isabelle Meyts; Qian Zhang; Margaret R MacDonald; Charles M Rice; Jean-Laurent Casanova; Emmanuelle Jouanguy; Xavier Bossuyt; Esra Hazar Sayar; Ismail Reisli; Alain Lefevre-Utile; Dick Zijlmans; Andrea Jurado; Ruben Pholien; Scott Drutman; Serkan Belkaya; Aurelie Cobat; Robbert Boudewijns; Dirk Jochmans; Johan Neyts; Yoann Seeleuthner; Lazaro Lorenzo-Diaz; Chibuzo Enemchukwu; Ian Tietjen; Hans-Heinrich Hoffmann; Mana Momenilandi; Laura Pöyhönen; Marilda M Siqueira; Sheila M Barbosa de Lima; Denise C de Souza Matos; Akira Homma; Maria de Lourdes S Maia; Tamiris Azamor da Costa Barros; Patricia Mouta Nunes de Oliveira; Emersom Ciclini Mesquita; Rik Gijsbers; Shen-Ying Zhang
Journal:  J Exp Med       Date:  2019-07-03       Impact factor: 14.307

4.  In memoriam: Stephen J Seligman, MD : Adverse reactions to the yellow fever vaccine: from epidemiological risk factors to causes and mechanisms.

Authors:  Jean-Laurent Casanova; Qian Zhang; Paul Bastard; Emmanuelle Jouanguy
Journal:  J Clin Immunol       Date:  2022-01-14       Impact factor: 8.542

5.  Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study.

Authors:  Valéria Valim; Ketty Lysie Libardi Lira Machado; Samira Tatiyama Miyamoto; Arthur Dalmaso Pinto; Priscila Costa Martins Rocha; Erica Vieira Serrano; Valquiria Garcia Dinis; Sônia Alves Gouvêa; João Gabriel Fragoso Dias; Ana Carolina Campi-Azevedo; Andréa Teixeira-Carvalho; Vanessa Peruhype-Magalhães; Ismael Artur da Costa-Rocha; Sheila Maria Barbosa de Lima; Emily Hime Miranda; Gisela Freitas Trindade; Maria de Lourdes de Sousa Maia; Maria Bernadete Renoldi de Oliveira Gavi; Lidia Balarini da Silva; Ruben Horst Duque; Ana Paula Espíndula Gianordoli; Thays Zanon Casagrande; Karine Gadioli Oliveira; Bruna Costa da Mata Moura; Fernanda Nicole-Batista; Luiza Correa Rodrigues; Thalles Brandão Clemente; Enan Sales Magalhães; Maria de Fatima Bissoli; Maria da Penha Gomes Gouvea; Lauro Ferreira da Silva Pinto-Neto; Carolina Zorzanelli Costa; Raquel Altoé Giovelli; Leticia Resende Brandão; Elizandra Tomazela Laurenti Polito; Ingrid de Oliveira Koehlert; Brunela Passos Borjaille; Daniela Bergamim Pereira; Laiza Hombre Dias; Daniela Linhares Merlo; Luiz Fellipe Favoreto Genelhu; Flavia Zon Pretti; Maryella Dos Santos Giacomin; Ana Paula Neves Burian; Francieli Fontana Sutile Tardetti Fantinato; Gecilmara Salviato Pileggi; Lícia Maria Henrique da Mota; Olindo Assis Martins-Filho
Journal:  Front Immunol       Date:  2020-07-17       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.